Antihistone antibodies in scleroderma

Aurora Parodi, M. Drosera, L. Barbieri, A. Rebora

Research output: Contribution to journalArticlepeer-review


Background: Antihistone antibodies (AHA) are usually considered the serological marker of drug-induced lupus erythematosus, but recently they have been found in patients with systemic scleroderma (SSc) and morphea. Objective and Methods: We determined AHA in 43 patients with SSc, 4 patients with overlap syndrome and 11 with morphea. Results and Conclusions: AHA were demonstrated in 41.8% of the SSc patients and in 36.3% of the morphea patients. Only 1 patient with overlap syndrome had AHA. Our SSc patients with AHA had frequent cardiac and renal involvements suggesting a prognostic value of AHA. In our morphea patients AHA did not correlate with clinical features.

Original languageEnglish
Pages (from-to)16-18
Number of pages3
Issue number1
Publication statusPublished - 1995


  • Antihistone antibodies
  • Morphea
  • Scleroderma

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Antihistone antibodies in scleroderma'. Together they form a unique fingerprint.

Cite this